8 results
Phase IIb: To evaluate the most effective dosing schedule of trabectedin.Phase III: To evaluate whether trabectedin given as 1st line chemothearpy for advanced/metastatic soft tissue sarcoma prolongs progression free surivival, as compared to…
Primary Objective: To compare the pharmacokinetics of the needlefree system with the Apo-go penject. Secondary objectives: - To assess the clinical effect of Apo-go vs. de needlefree system, using an "automated tap score" and a "Timed…
The key objective of the study is to prove that trabectedin (Yondelis) and PLD prolong overall survival versus carboplatin + PLD, in patients with progressive ovarian cancer 6 to 12 months after completing previous platinum based chemotherapy.As…
Primary Objective• To explore the pharmacodynamic effects of topically applied omiganan • To explore the treatment effect of omiganan compared to placebo in uVIN patients Secondary Objectives• To assess safety and tolerability • To explore the…
Primary objective• To explore the pharmacodynamic effects on a target lesion of topically applied omiganan in AD patientsSecondary Objectives• To assess safety and tolerability in AD patients• To evaluate the efficacy of omiganan compared to placebo…
Primary Objectives* To explore the pharmacodynamic effects of topically applied omiganan in patients with external genital warts* To explore clinical efficacy of omiganan compared to placebo in patients with external genital warts.Secondary…
Primary Objective- To assess efficacy and pharmacodynamic effects of topical omiganan BID Secondary Objectives- To assess safety and tolerability of topical omiganan BID
The objective of the study is to investigate whether trabectedin demonstrates sufficient antitumor activity against recurrent grade II or III to justify further investigation in phase III or as adjuvant therapy for newly diagnosed disease after…